AN ASIAN, PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 14-WEEK STUDY OF DS-5565 IN PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN FOLLOWED BY A 52-WEEK OPEN-LABEL EXTENSION

Trial Profile

AN ASIAN, PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 14-WEEK STUDY OF DS-5565 IN PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN FOLLOWED BY A 52-WEEK OPEN-LABEL EXTENSION

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs Mirogabalin (Primary)
  • Indications Diabetic neuropathies; Neuropathic pain
  • Focus Registrational; Therapeutic Use
  • Acronyms REDUCER
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 01 Feb 2017 Status changed from recruiting to active, no longer recruiting.
    • 30 Sep 2016 Trial design for two phase III studies including this study presented at the 16th World Congress on Pain
    • 04 Feb 2015 Status changed from not yet recruiting to recruiting, as reported in a Daiichi Sankyo media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top